Ayvakit is safe long-term treatment for systemic mastocytosis
New results show Ayvakit (avapritinib) is an effective and safe long-term treatment for systemic mastocytosis (SM).
The data, announced by Sanofi company Blueprint Medicines, showed Ayvakit led to sustained symptom and quality-of-life benefits in indolent SM (ISM) after a median follow-up of more than three years, and extended survival rates in advanced SM after a median follow-up of more than four years. Across both forms of SM, Ayvakit showed bone health improvements reflecting disease-modifying effects, and a safety and tolerability profile consistent with previously reported results.
The findings were presented at the American Society of Hematology (ASH) Annual Meeting and Exposition, currently ongoing in Orlando, US.
“Our ASH data add to the substantial body of evidence generated since we initiated clinical development for systemic mastocytosis about a decade ago and reflect the transformative benefits Ayvakit has delivered since its FDA approval for advanced SM in 2021 and ISM in 2023,” said Mik Rinne, Head of Development at Blueprint Medicines.
“Ayvakit has become the global standard of care across the spectrum of the disease, with robust datasets highlighting sustained quality-of-life benefits in ISM, favourable survival outcomes in advanced SM and a well-characterised safety profile supporting chronic treatment.
“Our presentations reinforce the urgency to treat the root cause of SM to mitigate its significant health complications and underscore the role of Ayvakit as a best-in-class therapy for the long-term management of the disease.”
Systemic mastocytosis (SM) is a rare disease which causes the uncontrolled proliferation and activation of mast cells, resulting in chronic, severe and often unpredictable symptoms across multiple organ systems.
The vast majority of those affected have indolent systemic mastocytosis (ISM). Despite treatment with multiple symptom-directed therapies, patients with ISM frequently experience persistent symptoms including anaphylaxis, maculopapular rash, pruritus, diarrhoea, brain fog, fatigue and bone pain, as well as long-term health complications such as osteoporosis.
There were no approved therapies for ISM until 2023, when Ayvakit received US Food and Drug Administration (FDA) approval for this indication.
Bruno Quinney, Content Team, DDW
